Last updated on March 2019

A 12-week randomized, double-blind, parallel-group, placebo-controlled study to determine the efficacy and safety of biphasic remogliflozin etabonate when administered to subjects with type 2 diabetes mellitus.

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Diabetes Mellitus | Type 2
  • Age: 18 Years
  • Gender: Male or Female

Inclusion Criteria:

  • T2DM with HbA1c 7.0-10.5% using no ADMs or metformin alone.

Exclusion Criteria:

  • eGFR less than 30
  • 2 or more UTI's in past 12 months
  • Malignancy within past 3 years
  • Working night shift and sleeping during the day

Recruitment Status: Closed

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.